Alimera reports net loss for fourth quarter, full year
Alimera Sciences reported a GAAP net loss of $14.8 million, or $0.47 per common share, for the fourth quarter of 2013, compared with a GAAP net loss of $5.3 million, or $0.17 per common share, for the fourth quarter of 2012, according to a press release.
The loss was attributed to an increase in the fair value of Alimera’s derivative warrant liability, a non-cash unrealized foreign currency gain and inventory issues.
For the full year, GAAP net loss was $51.2 million, or $1.62 per common share, compared with $19.8 million, or $0.63 per common share, for 2012.
Quarterly non-GAAP adjusted net loss was $7.5 million, or $0.24 per common share, compared with a non-GAAP adjusted net loss of $8.4 million, or $0.27 per common share, in the prior year’s quarter.
Net revenue for the quarter was $935,000, compared with $758,000 the prior year.